Navigation Links
BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien
Date:11/21/2011

SUNNYVALE, Calif., Nov. 21, 2011 /PRNewswire/ -- BARRX Medical Inc., a leader in developing minimally invasive medical devices used in conjunction with endoscopy to remove precancerous tissue from the gastrointestinal tract, announces today that they have signed a definitive agreement to be acquired by Covidien.  Covidien is a leading global provider of healthcare products and a worldwide leader in advanced energy-based devices. 

Covidien will acquire all of the outstanding capital stock of BARRX, a private company, for approximately $325 million, with additional future earn out payments possible upon achievement of company milestones.  The transaction, subject to customary closing conditions, is expected to be completed by January 31, 2012.

BARRX developed and markets the HALOFLEX ablation system, inclusive of a radiofrequency generator and numerous ablation catheters, HALO90, HALO90 ULTRA, and HALO360+.  The HALO ablation catheters deliver RF energy to diseased tissue in the gastrointestinal tract resulting in a uniform and repeatable depth of ablation.  Surgeons and gastroenterologists use the HALO devices during non-surgical endoscopic procedures to remove pre-cancerous and cancerous tissue from the gastrointestinal tract and to reduce bleeding associated with certain chronic disease states.

"We are extremely pleased that Covidien has elected to acquire BARRX, as this will allow us to continue our growth and avail our endoscopic therapy to patients with Barrett's esophagus and esophageal squamous cell neoplasia on a worldwide basis," said Greg Barrett, President and CEO, BARRX Medical.  "Covidien is a global leader in multiple disciplines of surgery and the acquisition of BARRX will allow them to leverage their expertise and resources in the growing field of endoscopy and gastrointestinal disorders."

"BARRX Medical products and technology complement our current portfolio of energy-based products and will broaden our presence in the global gastrointestinal market," said Bryan Hanson, Group President, Surgical Solutions.  "At the same time, patients will benefit from advances in RF technologies that will change the standard of care for esophageal diseases from invasive surgery to therapeutic intervention.   Covidien offers advantages to BARRX Medical that support its mission in long-term growth and value to patients.  We expect to leverage the BARRX technology and capabilities as a platform to accelerate global expansion."

"In today's healthcare environment, patients, physicians, payers and regulators demand that medical interventions be supported by a broad base of clinical evidence," said David S. Utley, M.D., Chief Medical Officer, BARRX Medical.  "A decade ago, BARRX recognized this need for an evidence-based approach for product and procedure development and, therefore, conducted a large number of clinical trials which have demonstrated the safety, efficacy, durability, and cost-utility of the HALO ablation system for treating Barrett's esophagus and esophageal squamous cell neoplasia."

About BARRX Medical, Inc.

BARRX Medical, Inc. develops endoscopic treatment solutions for Barrett's esophagus and other gastroenterological diseases such as esophageal squamous cell neoplasia, bleeding associated with radiation proctopathy, and bleeding associated with gastric antral vascular ectasia.  Barrett's esophagus is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD, and can lead to esophageal adenocarcinoma.  Esophageal squamous cell neoplasia is the precursor to the most common type of esophageal cancer (squamous cell carcinoma), which results in over 400,000 deaths per year worldwide.  The company's HALO90, HALO90 ULTRA and HALO360+ ablation catheters, powered by the HALOFLEX ablation system, provide a uniform and controlled ablation effect, which removes diseased tissue and allows re-growth of normal cells.

Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held.  Additional information is available at www.barrx.com.


'/>"/>
SOURCE BARRX Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Provides 510k Clearance for BARRX Medicals HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE)
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
5. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
6. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
9. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
10. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
11. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis released safe ... as benzodiazepines, developed with the help of a ... that are frequently prescribed for anxiety or insomnia," ... with opioid pain medications, benzodiazepines pose a significant ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... to their offering. ... The global chromatography market to grow at ... Chromatography Market 2016-2020, has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for ... and wellness program, at their world headquarters of Omni La Costa Resort & Spa ... to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):